SavedAdd your journal

Journals / MN Kardiyoloji / 2002 / Cilt: 9 - Sayı: 6

The long term effect of ramipril on patients with impaired glucose tolerance

Ramiprilin uzun dönemde bozulmuş glukoz toleranslı vakalar üzerindeki etkisi

Mehmet AKBULUT
Yılmaz ÖZBAY
Ilgın KARACA
Erdoğan İLKAY
Kemal AYDIN
Nadi ARSLAN
Pages
411–415
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: It was assumed that while ramipril increased the conversion of IGT to normal in normotensive cases with IGT, decreased major cardiovascular events and development of de novo diabetes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: In this study, we aimed to investigate the long term effect of ramipril in normotensive cases with impaired glucose tolerance according to criteria of American Diabetes Association (ADA).
📊
Key Findings & Data:MATERIAL AND METHOD: One hundred fifty two normotensive cases with impaired glucose tolerance (IGT) were included in this study. 2.5 mg ramipril+diet were given to 76 cases, placebo+diet to other 76 cases for an average of 47±4 months.
💡
Conclusion & Impact:CONCLUSION: It was assumed that while ramipril increased the conversion of IGT to normal in normotensive cases with IGT, decreased major cardiovascular events and development of de novo diabetes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glukoz intoleransı · Biyokimya · Koroner anjiyografi

Abstract

AIM: In this study, we aimed to investigate the long term effect of ramipril in normotensive cases with impaired glucose tolerance according to criteria of American Diabetes Association (ADA). MATERIAL AND METHOD: One hundred fifty two normotensive cases with impaired glucose tolerance (IGT) were included in this study. 2.5 mg ramipril+diet were given to 76 cases, placebo+diet to other 76 cases for an average of 47±4 months. Clinical and laboratory investigations of all cases were recorded by 24 week intervals. RESULTS: At the end of the study, in the ramipril group the number of cases whose impaired glucose tolerance improved was higher (p=0.001). However the number of the cases that new diabetes developed and who had major cardiovascular events (myocardial infarction, cardiac arrest, stroke, revascularization procedure, heart failure) were higher in placebo group (p=0.033, p=0.021). CONCLUSION: It was assumed that while ramipril increased the conversion of IGT to normal in normotensive cases with IGT, decreased major cardiovascular events and development of de novo diabetes.

Özet

AMAÇ: Bu çalışmada, American Diabetes Association (ADA) kriterlerine göre bozulmuş glukoz toleranslı normotansif vakalarda, ramipril'in uzun dönemde etkisini incelemeyi amaçladık. GEREÇ VE YÖNTEM: Çalışmaya, normotansif bozulmuş glukoz toleranslı 152 vaka alındı. Ortalama 47±4 ay süre ile, 76 vakaya 2.5 mg ramipril+diyet; 76 vakaya da plesebo+diyet verildi. Tüm vakaların klinik ve laboratuvar incelemeleri 24 haftalık periyotlarla kaydedildi. BULGULAR: Çalışma süresinin sonunda, ramipril tedavi grubunda bozulmuş glukoz toleransı (BGT) düzelen vaka sayısı daha fazlaydı (p:0.001). Ancak tüm major kardiyovasküler olaylar (miyokard infarktüsü, kardiyak arrest, inme, revaskülarizasyon işlemleri, kalp yetersizliği) ve yeni diabetes mellitus gelişim oranları, plesebo verilen gruba göre daha düşük olduğu görüldü (p:0.021, p:0.033). SONUÇ: Ramipril, normotansif BGT olan vakalarda BGT'nin normale dönüşümünü artırırken, major kardiyovasküler olayların ve yeni diabetes mellitus gelişimini azalttığı kanaatine varıldı.

🔖

Cite This Article

AKBULUT, M., ÖZBAY, Y., KARACA, I., İLKAY, E., AYDIN, K., ARSLAN, N. (2002). The long term effect of ramipril on patients with impaired glucose tolerance. MN Kardiyoloji, Cilt: 9 - Sayı: 6, 411–415. https://ajindex.com/articles/297640

References (11)

  1. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow up. Diabetologia 1991; 34:356-61.
  2. Ferranini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: The key of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
  3. Bvenholm O, Proudler A, Tornvall P, et al. Insulin intact and split proinsulin and coranary artery disease in young men. Circulation 1995;92:1422-9. Peter HB. Definition, diagnosis and classification of diabetes mellitus and impaired glucose tolerance. Joslin,s Diabetes Mellitus. A Waverly Company, Pennsylvania 1994:198-9.
  4. Keen H, Barnes DJ. The diagnosis and classification of diabetes mellitus and impaired glucose tolerance. Textbook of Diabetes 2nd. Blackwell Science Ltd, Philadelphia 1997:7-8.
  5. Harris Ml, Flegal KM, Cowie CC, et al. Prevalance of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes care 1998; 21:518-9.
  6. Melander A, Bitzen P-O, Sartor G, et al. Will Sulfonylurea treatment of impaired glucose tolerance delay development of complications of NIDDM? Diabetes Care 1990; 13:53-8.
  7. Jarrett RJ, Keen H, McCartney P. Whitehall Study: ten years follow up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabetic Med 1984; 1:279-83.
  8. Xiao-ren P, Guang-wei L, Ying-Hua H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance (The Da Qinq IGT and Diabetes Study) Diabetes Care 1997; 20:537-8.
  9. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19:1190-3.
  10. Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjest with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106:231-3.
  11. Antonucci T, Whitheomb R, McLain R, et al. Impaired glucose tolerance is.normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1998; 21:678-9. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-97. American Diabetes Assciation. Postprandial blood glucose. Diabetes Care 2001; 24:198-203. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects